Teoxane offers superior proposal to acquire Revance Therapeutics

Revance Therapeutics

06/01/2025 14:15

Jan 6 (Reuters) - Teoxane SA offered to acquire Revance
Therapeutics  RVNC.O  for a higher price compared to a buyout
offer from Crown Laboratories last month.
    Teoxane's proposal provides a 16% premium over the $3.10 per
share price in Revance's merger agreement with Crown
Laboratories on Dec. 9.

 (Reporting by Christy Santhosh in Bengaluru; Editing by
Shinjini Ganguli)
 ((Christy.Santhosh@thomsonreuters.com;))